Background: To describe the design of the baseline assessment of an epidemiological study of elderly persons living in Salamanca, central-western Spain: the Neurological Diseases in Salamanca (NEDISA) study. We assessed the epidemiology of stroke, cognitive disorders, essential tremor (ET), Parkinson’s disease (PD) and restless legs syndrome. Methods: In phase 1 (February 1 to May 31, 2007), 4 neurologists and 2 trained general physicians examined and performed phlebotomy on all participants. In phase 2 (June 1, 2007, to June 1, 2008), the participants were reexamined and had a complete neuropsychological assessment. Neuroimaging was performed in participants with cognitive disorders, ET and PD. Results: The registered study population consisted of 1,077 individuals, but 45 people were ineligible (address change, refusals or death), leaving a final sample of 1,032 (95.8%). The main demographic data on the 1,032 participants (408 men, 624 women) are provided. Conclusions: Most of the registered study population was enrolled, and this may have been due to the close relationship between NEDISA researchers and the general physicians in the area of study. The NEDISA study will likely improve our knowledge of prevalence rates of the neurological diseases chosen for study as well as the set of risk factors that predispose individuals in Spain to these disorders.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.